<SEC-DOCUMENT>0001213900-25-022445.txt : 20250311
<SEC-HEADER>0001213900-25-022445.hdr.sgml : 20250311
<ACCEPTANCE-DATETIME>20250311074527
ACCESSION NUMBER:		0001213900-25-022445
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250311
DATE AS OF CHANGE:		20250311

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OptimizeRx Corp
		CENTRAL INDEX KEY:			0001448431
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		ORGANIZATION NAME:           	07 Trade & Services
		IRS NUMBER:				261265381
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38543
		FILM NUMBER:		25725880

	BUSINESS ADDRESS:	
		STREET 1:		260 CHARLES STREET
		STREET 2:		SUITE 302
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		248-651-6558

	MAIL ADDRESS:	
		STREET 1:		260 CHARLES STREET
		STREET 2:		SUITE 302
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>ea0233917-defa14a_optimizerx.htm
<DESCRIPTION>SOLICITING MATERIAL UNDER 240.14A-12
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule 14A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Amendment No.&nbsp;&nbsp;&nbsp;&nbsp; )</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by the Registrant &#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by a party other than the Registrant &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Check the appropriate box:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9744; Preliminary Proxy Statement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9744; Confidential, for Use of the Commission Only (as permitted
by Rule 14a-6(e)(2))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9744; Definitive Proxy Statement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9744; Definitive Additional Materials</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9746; Soliciting Material under &sect; 240.14a-12</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 16pt"><B>OptimizeRx
Corporation</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Registrant as Specified In Its Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Person(s) Filing Proxy Statement, if
other than the Registrant)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Payment of Filing Fee (Check all boxes that apply): </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9746; No fee required</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9744; Fee paid previously with preliminary materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9744; Fee computed on table in exhibit required by Item 25(b) per
Exchange Act Rules 14a- 6(i)(1) and 0-11</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRx Corporation, a Nevada corporation (&ldquo;<U>OptimizeRx</U>&rdquo;),
is filing materials contained in this Schedule 14A with the U.S. Securities and Exchange Commission (&ldquo;<U>SEC</U>&rdquo;) in connection
with OptimizeRx&rsquo;s solicitation of proxies from its stockholders in connection with its 2025 Annual Meeting of Stockholders and at
any and all adjournments, postponements, continuations, and reschedulings thereof (the &ldquo;<U>2025 Annual Meeting</U>&rdquo;). OptimizeRx
has not filed a preliminary or definitive proxy statement with the SEC in connection with its solicitation of proxies to be used at the
2025 Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Press Release Issued on March 11, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attached hereto is a press release issued by OptimizeRx
on March 11, 2025. This press release is being filed herewith&nbsp;because it may be deemed&nbsp;to be solicitation material in connection
with OptimizeRx&rsquo;s solicitation of proxies to be used at the 2025 Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Important Additional Information And Where To Find It</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimIzeRx Corporation (the &ldquo;<U>Company</U>&rdquo;)
plans to file proxy materials with the U.S. Securities and Exchange Commission (the &ldquo;<U>SEC</U>&rdquo;) in connection with the solicitation
of proxies for the Company's 2025 annual meeting of stockholders (the &ldquo;<U>2025 Annual Meeting</U>&rdquo;). Prior to the 2025 Annual
Meeting, the Company will file a definitive proxy statement (the &ldquo;<U>Proxy Statement</U>&rdquo;) together with a <B><U>WHITE</U></B>
proxy card.&nbsp; STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT
DOCUMENTS THAT THE COMPANY WILL FILE WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION. Stockholders will be able to obtain, free of charge, copies of the Proxy Statement, any amendments or supplements
thereto, and any other documents (including the <B><U>WHITE</U></B> proxy card) when filed by the Company with the SEC at the SEC's website
(http://www.sec.gov) or at the Company's website at&nbsp;https://www.optimizerx.com/
or by contacting&nbsp;Andy D&rsquo;Silva, SVP - Finance, by email at&nbsp;adsilva@optimizerx.com
or by mail at OptimizeRx Corporation, 260 Charles Street, Suite 302, Waltham, MA 02453.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certain Information Regarding Participants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, its directors, certain of its executive
officers, and other employees may be deemed to be &ldquo;participants&rdquo; (as defined in Section&nbsp;14(a) of the Securities Exchange
Act of 1934, as amended) in the solicitation of proxies from stockholders in connection with the 2025 Annual Meeting.&nbsp;Additional
information regarding the identity of these participants and their direct or indirect interests, by security holdings or otherwise, will
be set forth in the Proxy Statement and other materials to be filed with the SEC in connection with the 2025 Annual Meeting.&nbsp;Information
relating to the foregoing can also be found in the Company's definitive proxy statement for its 2024 annual meeting of stockholders,
filed with the SEC on&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1448431/000121390024036855/ea0204731-01.htm">April 29, 2024</A>.&nbsp;To
the extent holdings of such participants in the Company's securities have changed since the amounts described in the 2024 proxy statement,
such changes have been reflected in the following Statements of Change in Beneficial Ownership on Form&nbsp;4 filed with the SEC with
respect to the Company: Form&nbsp;4, filed by&nbsp;Stephen L. Silvestro on <A HREF="https://www.sec.gov/Archives/edgar/data/1773461/000162828025009631/xslF345X05/wk-form4_1741097894.xml">March
4, 2025</A>; Form&nbsp;4, filed by&nbsp;Stephen L. Silvestro on <A HREF="https://www.sec.gov/Archives/edgar/data/1773461/000162828025006689/xslF345X05/wk-form4_1740076754.xml">February
20, 2025</A>; Form&nbsp;4, filed by&nbsp;Edward Stelmakh on <A HREF="https://www.sec.gov/Archives/edgar/data/1887046/000162828025006691/xslF345X05/wk-form4_1740076800.xml">February
20, 2025</A>; Form&nbsp;4, filed by&nbsp;Cathy Klema on <A HREF="https://www.sec.gov/Archives/edgar/data/1181157/000162828025003855/xslF345X05/wk-form4_1738713024.xml">February
4, 2025</A>; Form&nbsp;4/A, filed by&nbsp;Edward Stelmakh on <A HREF="https://www.sec.gov/Archives/edgar/data/1887046/000162828024052517/xslF345X05/wk-form4a_1735335531.xml">December
27, 2024</A>; Form&nbsp;4, filed by&nbsp;Stephen L. Silvestro on <A HREF="https://www.sec.gov/Archives/edgar/data/1773461/000162828024052490/xslF345X05/wk-form4_1735330727.xml">December
27, 2024</A>; Form&nbsp;4, filed by&nbsp;Edward Stelmakh on <A HREF="https://www.sec.gov/Archives/edgar/data/1887046/000162828024052522/xslF345X05/wk-form4_1735336822.xml">December
27, 2024</A>; Form&nbsp;4, filed by&nbsp;Edward Stelmakh on <A HREF="https://www.sec.gov/Archives/edgar/data/1887046/000162828024052284/xslF345X05/wk-form4_1734741993.xml">December
20, 2024</A>; Form&nbsp;4, filed by&nbsp;Stephen L. Silvestro on <A HREF="https://www.sec.gov/Archives/edgar/data/1773461/000162828024052286/xslF345X05/wk-form4_1734742056.xml">December
20, 2024</A>; Form&nbsp;4, filed by&nbsp;Edward Stelmakh on <A HREF="https://www.sec.gov/Archives/edgar/data/1887046/000162828024042848/xslF345X05/wk-form4_1729025612.xml">October
15, 2024</A>; Form&nbsp;4, filed by&nbsp;Stephen L. Silvestro on <A HREF="https://www.sec.gov/Archives/edgar/data/1773461/000162828024042475/xslF345X05/wk-form4_1728350678.xml">October
7, 2024</A>; Form&nbsp;4, filed by&nbsp;Edward Stelmakh on <A HREF="https://www.sec.gov/Archives/edgar/data/1887046/000162828024042477/xslF345X05/wk-form4_1728351009.xml">October
7, 2024</A>; Form&nbsp;4, filed by&nbsp;Gregory D. Wasson on <A HREF="https://www.sec.gov/Archives/edgar/data/1188827/000162828024027714/xslF345X05/wk-form4_1718142520.xml">June
11, 2024</A>; Form&nbsp;4, filed by&nbsp;Cathy Klema on <A HREF="https://www.sec.gov/Archives/edgar/data/1181157/000162828024027710/xslF345X05/wk-form4_1718142449.xml">June
11, 2024</A>; Form&nbsp;4, filed by&nbsp;Ellen O&rsquo;Connor Vos on <A HREF="https://www.sec.gov/Archives/edgar/data/1534357/000162828024027715/xslF345X05/wk-form4_1718142583.xml">June
11, 2024</A>; Form&nbsp;4, filed by&nbsp;James Paul Lang on <A HREF="https://www.sec.gov/Archives/edgar/data/1703090/000162828024027709/xslF345X05/wk-form4_1718142412.xml">June
11, 2024</A>; Form&nbsp;4, filed by&nbsp;Patrick Spangler on <A HREF="https://www.sec.gov/Archives/edgar/data/1296525/000162828024027716/xslF345X05/wk-form4_1718142621.xml">June
11, 2024</A>; Form&nbsp;4/A, filed by&nbsp;Stephen L. Silvestro on <A HREF="https://www.sec.gov/Archives/edgar/data/1773461/000162828024020819/xslF345X05/wk-form4a_1715045619.xml">May
6, 2024</A>; Form&nbsp;4, filed by&nbsp;Stephen L. Silvestro on <A HREF="https://www.sec.gov/Archives/edgar/data/1773461/000162828024020821/xslF345X05/wk-form4_1715045740.xml">May
6, 2024</A>; and Form&nbsp;4/A, filed by&nbsp;Stephen L. Silvestro on <A HREF="https://www.sec.gov/Archives/edgar/data/1773461/000162828024020817/xslF345X05/wk-form4a_1715045531.xml">May
6, 2024</A>. These filings can be found at the SEC's website at&nbsp;www.sec.gov. More
detailed and updated information regarding the identity of participants in the solicitation, and their direct or indirect interests (by
security holdings or otherwise), will be set forth in the Proxy Statement and other materials to be filed with the SEC. These documents
can be obtained free of charge from the sources indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OptimizeRx Corporation Confirms Receipt </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of Notice of Director Nominations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>No Stockholder Action Required at this Time</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WALTHAM, MA &ndash; March 11, 2025 &ndash;
</B>OptimizeRx Corp. (the &ldquo;Company&rdquo;)&nbsp;(Nasdaq: OPRX), a leading provider of
healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today confirmed
that it has received a purported notice of nominations from a stockholder, Whetstone Capital Advisors, LLC, regarding its intention to
nominate two candidates for election to the OptimizeRx Board of Directors at the Company&rsquo;s 2025 Annual Meeting of Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The OptimizeRx Board of Directors will make its
formal recommendation regarding director nominations in the Company&rsquo;s definitive proxy statement which will be filed with the Securities
and Exchange Commission and mailed to stockholders eligible to vote at the Company&rsquo;s 2025 Annual Meeting of Stockholders, which
has not yet been scheduled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About OptimizeRx</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRx is a leading healthcare technology
company that&rsquo;s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative
AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant,
and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions
that drive faster treatment decisions and improved patient outcomes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our commitment to privacy-safe, patient-centric
technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients
at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world&rsquo;s leading pharmaceutical
and life sciences companies to transform the healthcare landscape and create a healthier future for all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Important Cautions Regarding Forward-Looking
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &ldquo;anticipates&rdquo;, &ldquo;believes&rdquo;,
&ldquo;estimates&rdquo;, &ldquo;expects&rdquo;, &ldquo;forecasts&rdquo;, &ldquo;intends&rdquo;, &ldquo;plans&rdquo;, &ldquo;projects&rdquo;,
&ldquo;targets&rdquo;, &ldquo;designed&rdquo;, &ldquo;could&rdquo;, &ldquo;may&rdquo;, &ldquo;should&rdquo;, &ldquo;will&rdquo; or other
similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect
the Company's expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact,
are forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company&rsquo;s current
expectations and involve assumptions regarding the Company's business, the economy, and other future conditions that may never materialize
or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted,
or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements
as a result of various risks and uncertainties including, but not limited to, the effect of government regulation, seasonal trends, dependence
on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and
evolving technology, the ability to maintain contracts with electronic prescription platforms and electronic health records networks,
competition, and other factors discussed in the Company&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2023, and in
other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking
statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Important Additional Information And Where To Find It</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimIzeRx Corporation (the &ldquo;Company&rdquo;)
plans to file proxy materials with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) in connection with the solicitation
of proxies for the Company's 2025 annual meeting of stockholders (the &ldquo;2025 Annual Meeting&rdquo;). Prior to the 2025 Annual Meeting,
the Company will file a definitive proxy statement (the &ldquo;Proxy Statement&rdquo;) together with a <B><U>WHITE</U></B> proxy card.&nbsp;
STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS
THAT THE COMPANY WILL FILE WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION. Stockholders will be able to obtain, free of charge, copies of the Proxy Statement, any amendments or supplements thereto
and any other documents (including the <B><U>WHITE</U></B> proxy card) when filed by the Company with the SEC at the SEC's website (http://www.sec.gov)
or at the Company's website at&nbsp;https://www.optimizerx.com/ or by contacting&nbsp;Andy D&rsquo;Silva,
SVP - Finance, by email at&nbsp;adsilva@optimizerx.com or by mail at OptimizeRx Corporation,
260 Charles Street, Suite 302, Waltham, MA 02453.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certain Information Regarding Participants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, its directors, certain of its executive
officers, and other employees may be deemed to be &ldquo;participants&rdquo; (as defined in Section&nbsp;14(a) of the Securities Exchange
Act of 1934, as amended) in the solicitation of proxies from stockholders in connection with the 2025 Annual Meeting.&nbsp;Additional
information regarding the identity of these participants and their direct or indirect interests, by security holdings or otherwise, will
be set forth in the Proxy Statement and other materials to be filed with the SEC in connection with the 2025 Annual Meeting.&nbsp;Information
relating to the foregoing can also be found in the Company's definitive proxy statement for its 2024 annual meeting of stockholders, filed
with the SEC on&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1448431/000121390024036855/ea0204731-01.htm">April 29, 2024</A>.&nbsp;To
the extent holdings of such participants in the Company's securities have changed since the amounts described in the 2024 proxy statement,
such changes have been reflected in the following Statements of Change in Beneficial Ownership on Form&nbsp;4 filed with the SEC with
respect to the Company: Form&nbsp;4, filed by&nbsp;Stephen L. Silvestro on <A HREF="https://www.sec.gov/Archives/edgar/data/1773461/000162828025009631/xslF345X05/wk-form4_1741097894.xml">March
4, 2025</A>; Form&nbsp;4, filed by&nbsp;Stephen L. Silvestro on  <A HREF="https://www.sec.gov/Archives/edgar/data/1773461/000162828025006689/xslF345X05/wk-form4_1740076754.xml">February
20, 2025</A>; Form&nbsp;4, filed by&nbsp;Edward Stelmakh on <A HREF="https://www.sec.gov/Archives/edgar/data/1887046/000162828025006691/xslF345X05/wk-form4_1740076800.xml">February
20, 2025</A>; Form&nbsp;4, filed by&nbsp;Cathy Klema on <A HREF="https://www.sec.gov/Archives/edgar/data/1181157/000162828025003855/xslF345X05/wk-form4_1738713024.xml">February
4, 2025</A>; Form&nbsp;4/A, filed by&nbsp;Edward Stelmakh on <A HREF="https://www.sec.gov/Archives/edgar/data/1887046/000162828024052517/xslF345X05/wk-form4a_1735335531.xml">December
27, 2024</A>; Form&nbsp;4, filed by&nbsp;Stephen L. Silvestro on <A HREF="https://www.sec.gov/Archives/edgar/data/1773461/000162828024052490/xslF345X05/wk-form4_1735330727.xml">December
27, 2024</A>; Form&nbsp;4, filed by&nbsp;Edward Stelmakh on <A HREF="https://www.sec.gov/Archives/edgar/data/1887046/000162828024052522/xslF345X05/wk-form4_1735336822.xml">December
27, 2024</A>; Form&nbsp;4, filed by&nbsp;Edward Stelmakh on <A HREF="https://www.sec.gov/Archives/edgar/data/1887046/000162828024052284/xslF345X05/wk-form4_1734741993.xml">December
20, 2024</A>; Form&nbsp;4, filed by&nbsp;Stephen L. Silvestro on <A HREF="https://www.sec.gov/Archives/edgar/data/1773461/000162828024052286/xslF345X05/wk-form4_1734742056.xml">December
20, 2024</A>; Form&nbsp;4, filed by&nbsp;Edward Stelmakh on <A HREF="https://www.sec.gov/Archives/edgar/data/1887046/000162828024042848/xslF345X05/wk-form4_1729025612.xml">October
15, 2024</A>; Form&nbsp;4, filed by&nbsp;Stephen L. Silvestro on <A HREF="https://www.sec.gov/Archives/edgar/data/1773461/000162828024042475/xslF345X05/wk-form4_1728350678.xml">October
7, 2024</A>; Form&nbsp;4, filed by&nbsp;Edward Stelmakh on <A HREF="https://www.sec.gov/Archives/edgar/data/1887046/000162828024042477/xslF345X05/wk-form4_1728351009.xml">October
7, 2024</A>; Form&nbsp;4, filed by&nbsp;Gregory D. Wasson on <A HREF="https://www.sec.gov/Archives/edgar/data/1188827/000162828024027714/xslF345X05/wk-form4_1718142520.xml">June
11, 2024</A>; Form&nbsp;4, filed by&nbsp;Cathy Klema on <A HREF="https://www.sec.gov/Archives/edgar/data/1181157/000162828024027710/xslF345X05/wk-form4_1718142449.xml">June
11, 2024</A>; Form&nbsp;4, filed by&nbsp;Ellen O&rsquo;Connor Vos on <A HREF="https://www.sec.gov/Archives/edgar/data/1534357/000162828024027715/xslF345X05/wk-form4_1718142583.xml">June
11, 2024</A>; Form&nbsp;4, filed by&nbsp;James Paul Lang on <A HREF="https://www.sec.gov/Archives/edgar/data/1703090/000162828024027709/xslF345X05/wk-form4_1718142412.xml">June
11, 2024</A>; Form&nbsp;4, filed by&nbsp;Patrick Spangler on <A HREF="https://www.sec.gov/Archives/edgar/data/1296525/000162828024027716/xslF345X05/wk-form4_1718142621.xml">June
11, 2024</A>; Form&nbsp;4/A, filed by&nbsp;Stephen L. Silvestro on <A HREF="https://www.sec.gov/Archives/edgar/data/1773461/000162828024020819/xslF345X05/wk-form4a_1715045619.xml">May
6, 2024</A>; Form&nbsp;4, filed by&nbsp;Stephen L. Silvestro on <A HREF="https://www.sec.gov/Archives/edgar/data/1773461/000162828024020821/xslF345X05/wk-form4_1715045740.xml">May
6, 2024</A>; and Form&nbsp;4/A, filed by&nbsp;Stephen L. Silvestro on <A HREF="https://www.sec.gov/Archives/edgar/data/1773461/000162828024020817/xslF345X05/wk-form4a_1715045531.xml">May
6, 2024</A>. These filings can be found at the SEC's website at&nbsp;www.sec.gov. More
detailed and updated information regarding the identity of participants in the solicitation, and their direct or indirect interests (by
security holdings or otherwise), will be set forth in the Proxy Statement and other materials to be filed with the SEC. These documents
can be obtained free of charge from the sources indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>OptimizeRx&#8239;Contact</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Andy D&rsquo;Silva, SVP Corporate Finance&#8239;&#8239;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">adsilva@optimizerx.com&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Relations Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sandya von der Weid</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Advisors, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">svonderweid@lifesciadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  R 0(# 2(  A$! Q$!_\0
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M=\8==TG45M?$^ECRR?G(C,4BCUP>#3_LVO:^E^U]0^M4[GMU>4^"/B!KFO\
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M?4-7N(EDGMRL<.X9"9R21[\5ZUXFM8;SPOJD$Z!XVM9,@CN%)!^H-><_ ?\
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%HH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
